3 Dividend Stocks Built for Retirement to Buy in September

The article highlights Johnson & Johnson, Realty Income and JPMorgan as retirement-income stocks supported by dividend growth and cash-flow coverage. JNJ has raised its dividend for 64 consecutive years and guides FY2026 free cash flow toward $21B; Realty Income yields 5.45% with FY2026 AFFO guidance of $4.44-$4.45 per share; and JPMorgan raised its quarterly dividend 10% to $1.65 while authorizing $50B of buybacks. Key risks include JNJ's STELARA biosimilar erosion, Realty Income's rate and tenant-credit exposure, and JPMorgan's normalizing credit losses and macroeconomic risks.

Analysis

The three names have materially different factor exposures, so treating them as a single “safe income” basket obscures the main portfolio risk: O is duration- and credit-spread-sensitive, JPM is late-cycle beta, and JNJ is exposed to patent-cliff execution and litigation reserve uncertainty. The highest-quality income stream is not necessarily the best near-term trade; dividend announcements are largely anticipated, and valuation plus the next earnings revision will dominate returns over the next 1-3 months.

JNJ’s upside requires newer immunology, oncology, and cell-therapy franchises to outgrow the legacy-product erosion faster than consensus currently models. That can support a defensive multiple only if gross-margin mix holds and legal cash outflows remain contained; an adverse litigation reserve or slower uptake in high-cost therapies would make the dividend narrative irrelevant to the equity multiple. The more interesting second-order beneficiary of a successful specialty-drug ramp is likely contract manufacturers and oncology diagnostics suppliers, but JNJ itself remains the cleaner defensive expression against an economic slowdown.

O’s incremental investment activity is economically attractive only while its cost of capital stays below acquisition yields after financing and overhead. A modest rise in long-end Treasury yields or wider BBB/A credit spreads can erase the accretion embedded in external-growth assumptions, while weaker consumer tenants create a delayed AFFO problem through lease restructuring rather than immediate occupancy declines. JPM’s capital return is sustainable, but its valuation is most vulnerable to a normalization in investment-banking activity, reserve builds, or lower short rates compressing net interest income over 6-18 months.

Contrarian view: the market may be underpricing O’s financing sensitivity and overpricing JPM’s current-cycle earnings durability, while JNJ’s recent strength leaves little tolerance for pipeline or litigation disappointment. For a defensive income allocation, quality should be expressed through relative trades rather than equal-weight ownership.

Key Decisions for Investors

• Initiate a 3-6 month long JNJ / short XLV pair only on a post-earnings pullback: target relative upside from pipeline execution and defensive rotation; exit if management cuts medium-term operational growth expectations or legal cash charges exceed prior reserve assumptions.
• Avoid adding O ahead of the next major inflation and Treasury-supply releases. Reassess for a long position only if the 10-year Treasury and O’s unsecured borrowing spreads stabilize; a 50 bp rise in either materially weakens acquisition-spread economics and could drive further multiple compression.
• Maintain JPM as a capital-return holding but hedge cyclical exposure with a partial short in KRE over the next 3-6 months. JPM should outperform regional banks if credit normalizes, but reduce outright exposure if card-loss trends accelerate or management lowers net-interest-income guidance.
• Do not construct an equal-weight dividend basket. Size JNJ as the core defensive allocation, keep JPM smaller and tied to credit-cycle monitoring, and treat O as a tactical duration position rather than a bond substitute.